Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT

Journal of Nuclear Medicine

Volumn 41, Issue 7, 2000, Pages 1155-1162

  Kogure, Daiji ^b   Matsuda, Hiroshi ^a   Ohnishi, Takashi ^b   Asada, Takashi ^b   Masatake, Uno ^b   Kunihiro, Toshiyuki ^b   Nakano, Seigo ^b   Takasaki, Masaru ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^b NONE

Author keywords

Alzheimer's disease; Regional cerebral blood flow; SPECT; Statistical parametric mapping

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASSOCIATION CORTEX; BRAIN BLOOD FLOW; BRAIN MAPPING; BRAIN PERFUSION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CEREBROVASCULAR CIRCULATION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033927770     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. McGeer PL, Kamo H, Harrop R, et al. Companion of PET, MRI and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36:1569-1574.
2. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology. 1986;36:879-887.
3. Johnson KA, Holman BL, Mueller SP, et al. Single photon emission computed tomography in Alzheimer's disease: abnormal iofetamine I 123 uptake reflects dementia severity. Arch Neurol. 1988;45:392-396.
4. Pearlson GD, Harris GJ, Powers RE, et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease. Arch Gen Psychiatry. 1992;49:402-408.
5. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Human Brain Function. 1st ed. San Diego, CA: Academic Press; 1997:3-159.
6. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994:123-163.
7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology. 1984;34:939-944.
8. Hughes CP, Berg L, Denziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
9. Hodges JR. Cognitive Assessment for Clinician. 1st ed. Oxford, England: Oxford Medical Publications; 1993:197-228.
10. Hodges JR, Patterson K. Is semantic memory consistently impaired early in the course of Alzheimer's disease? Neuroanatomical and diagnostic implications. Neuropsychologia. 1995;33:441-459.
11. Matsuda H, Yagishita A, Tsuji S, Hisada K. A quantitative approach to technetium-99m ethyl cysteinate dimer: a comparison with technetium-99m hexamethylpropylene amine oxime. Eur J Nucl Med. 1995;22:633-637.
12. 99mTc-ECD consecutive SPECT method. J Cereb Blood Flow Metab. 1997;17:1020-1032.
13. 99mTc-bicisate in the human brain after intracarotid injection. J Cereb Blood Flow Metab. 1994;14(suppl 1):S19-S27.
14. Imon Y, Matsuda H, Ogawa M, Kogure D, Sunohara N. SPECT image analysis in Parkinson's disease subjects using statistical parametric mapping. J Nucl Med. 1999;40:1583-1589.
15. Talairach J, Tournoux P. Co-Planar Stereotactic Atlas of the Human Brain. 1st ed. Stuttgart, Germany: Thieme; 1988:37-110.
16. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab. 1991;11:690-699.
17. Friston KJ, Worsley KJ, Frackowiak RSJ, Mazziotta JC, Evans AC. Assessing the significance of focal activations using their spatial extent. Hum Brain Mapping. 1994;1:214-220.
18. Minoshima S, Foster NL, Kuhl DH. Posterior cingulate cortex in Alzheimer's disease. Lancet. 1994;344:895.
19. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
20. 15O positron emission tomography. Eur J Nucl Med. 1997;24:670-673.
21. Ibanez V, Pietrini P, Alexandar GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1998;50:1585-1593.
22. Desgranges E, Baron J-C, Sayette V, et al. The neural substrates of memory systems impairment in Alzheimer's disease: a PET study of resting glucose utilization. Brain. 1998;121:611-631.
23. Fletcher PC, Frith CD, Grasby PM, Shallice T, Frackowiak RSJ, Dolan RJ. Brain systems for encoding and retrieval of auditory-verbal memory. Brain. 1995;118: 401-416.
24. Valenstein E, Bowers D, Verfaellie M, Heilman KM, Day A, Watson RT. Retrosplenial amnesia. Brain. 1987;110:1631-1646.
25. Rudge P, Warrington EK. Selective impairment of memory and visual perception in splenial tumours. Brain. 1991;114:349-360.
26. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer's disease: a reference region for functional brain image (PET) analysis. J Compta Assist Tomogr. 1995;19:541-547.
27. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-256.
28. Gomez-Isla T, Price TL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II enthorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491-4500.
29. Jack CR, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997;49:786-794.
30. Bobinski M, Leon MJ, Convit A, et al. MRI of enthorhinal cortex in mild Alzheimer's disease. Lancet. 1999;353:38-40.
31. Ohnishi T, Hoshi H, Nagamachi S, et al. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatrie diseases. J Nucl Med. 1995;36:1163-1169.
32. Julin P, Lindqvist J, Svensson L, Slomka P, Wahlund LO. MRI-guided SPECT measurements of medial temporal lobe blood flow in Alzheimer's disease. J Nucl Med. 1997;38:914-919.
33. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: a correlative study. J Nucl Med. 1999;40:522-529.
34. Kitayama N, Kogure D, Ohnishi T, et al. MRI-based volumetry of hippocampal gray-matter, and SPECT measurements of hippocampal blood flow for the diagnosis of Alzheimer's disease: comparison with statistical parametric mapping. Brain Sci Ment Disord. 1999;10:299-306.
35. Mori E, Yoneda Y, Yamashita H, Hirono N, Ikeda M, Yamadori A. Medial temporal structures relate to memory impairment in Alzheimer's disease: an MRI volumetric study. J Neurol Neurosurg Psychiatry. 1997;63:214-221.
36. Tohgi H, Takahashi S, Kato E, et al. Reduced size of right hippocampus in 39-to 80-year old normal subjects carrying the apolipoprotein E ε4 allele. Neurosci Lett. 1997;236:21-24.
37. Lehtovirta M, Kuikka J, Helisalmi S, et al. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry. 1998;64:742-746.
38. Haxby JV, Grady CL, Koss E, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990;47:753-760.
39. Smith GS, Leon ML, George AE, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease: pathophysiologic implications. Arch Neurol. 1992;49:1142-1150.
40. Brown DRP, Hunter R, Wyper DJ, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: a SPECT blood flow study. J Psychiatr Res. 1996;30:109-126.